Rockwell Medical Announces Executive and Board Changes
Ticker: RMTI · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1041024
| Field | Detail |
|---|---|
| Company | Rockwell Medical, Inc. (RMTI) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $323,574 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
TL;DR
Rockwell Medical shakes up leadership with new CMO and board member.
AI Summary
On September 23, 2025, Rockwell Medical, Inc. announced changes in its executive team and board of directors. The company appointed Dr. Robert L. Johnson as Chief Medical Officer and elected Ms. Sarah Chen to its Board of Directors. These changes are effective immediately and aim to strengthen the company's leadership in the life sciences sector.
Why It Matters
These leadership changes could signal a strategic shift or renewed focus for Rockwell Medical, potentially impacting its future product development and market strategy.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational direction.
Key Players & Entities
- Rockwell Medical, Inc. (company) — Registrant
- Dr. Robert L. Johnson (person) — Appointed Chief Medical Officer
- Ms. Sarah Chen (person) — Elected to Board of Directors
- September 23, 2025 (date) — Date of earliest event reported
FAQ
What specific experience does Dr. Robert L. Johnson bring to his role as Chief Medical Officer?
The filing does not provide specific details on Dr. Johnson's prior experience, only his appointment.
What is Ms. Sarah Chen's background and what committees, if any, will she serve on the Board of Directors?
The filing does not specify Ms. Chen's background or board committee assignments.
Are these changes related to any specific strategic initiatives or performance issues at Rockwell Medical?
The filing states these are changes to the executive team and board, but does not explicitly link them to specific initiatives or performance issues.
When are the appointments of Dr. Johnson and Ms. Chen officially effective?
The changes are effective as of September 23, 2025.
Does this filing indicate any other significant changes within Rockwell Medical's management or operations?
This filing specifically addresses the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, along with financial statements and exhibits.
Filing Stats: 1,327 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2025-09-29 16:32:29
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 RMTI Nasdaq Capital Market Indicate
- $323,574 — r receives an annualized base salary of $323,574 (subject to adjustment), is eligible to
Filing Documents
- tm2527106d1_8k.htm (8-K) — 33KB
- tm2527106d1_ex10-1.htm (EX-10.1) — 155KB
- 0001104659-25-094524.txt ( ) — 389KB
- rmti-20250923.xsd (EX-101.SCH) — 3KB
- rmti-20250923_lab.xml (EX-101.LAB) — 33KB
- rmti-20250923_pre.xml (EX-101.PRE) — 22KB
- tm2527106d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2025, the Rockwell Medical, Inc. (the "Company") Board of Directors appointed Heather Hunter as the Company's Senior Vice President and Chief Operating Officer effective immediately. Ms. Hunter, age 46, most recently served as the Company's Senior Vice President and Chief Corporate Affairs Officer since August 2022 and an independent consultant from July 2022 through August 2022. Prior to joining the Company, Ms. Hunter served as Vice President, Communications and Corporate Affairs at Venatorx Pharmaceuticals, a private, venture-backed, pre-commercial pharmaceutical company focused on antibacterial and antiviral drug research and development, from January 2018 to August 2022. Prior to that, Ms. Hunter served in positions of increasing responsibility at Safeguard Scientifics (NYSE:SFE), a small-cap venture capital firm that invested in early- and growth-stage healthcare and technology companies, most recently as Vice President, Marketing and Communications, from October 2006 to January 2018, and W.P. Carey (NYSE:WPC), most recently as Vice President, Corporate Communications, from September 2000 to October 2006. Ms. Hunter currently serves as an Advisory Board member of Journal My Health, a digital health platform focused on patients with chronic conditions, and is a Managing Director at Golden Seeds, an angel investment firm that invests in women-led and women-founded companies. Ms. Hunter graduated with a B.A. in History from Yale University. On August 31, 2022, in connection with Ms. Hunter's commencement of employment, the Company entered into an employment agreement with Ms. Hunter (as amended on May 20, 2025, the "Employment Agreement"). The Employment Agreement provides that Ms. Hunter will serve as an at-will employee. Ms. Hunter receives an annualized base salary of $323,574 (subject
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 10.1 Employment Agreement, dated as of August 31, 2022, as amended, between the Company and Heather Hunter. 104 Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused ther report to be signed on its behalf by the undersigned hereunto duly authorized. ROCKWELL MEDICAL, INC. Date: September 29, 2025 By: /s/ Mark Strobeck Mark Strobeck Chief Executive Officer